Enliven Therapeutics(US:ELVN)2024-11-13 21:10Financial Performance - The net loss for Q3 2024 was $23.2 million, compared to a net loss of $20.8 million in Q3 2023[9] - Enliven's total operating expenses for Q3 2024 were $27.1 million, compared to $24.2 million in Q3 2023[13] - Research and development (R&D) expenses increased to $21.3 million in Q3 2024 from $19.6 million in Q3 2023, while general and administrative (G&A) expenses rose to $5.8 million from $4.6 million in the same period[9] Cash and Assets - The company had cash, cash equivalents, and marketable securities totaling $291.8 million as of September 30, 2024, providing a cash runway into late 2026[9] - The company’s total assets increased to $305.4 million as of September 30, 2024, up from $271.9 million at the end of 2023[14] - Enliven's stockholders' equity rose to $288.4 million as of September 30, 2024, compared to $245.9 million at the end of 2023[14] Clinical Development - Enliven Therapeutics reported a cumulative major molecular response (MMR) rate of 44.4% (8/18) for ELVN-001 in a Phase 1 clinical trial for chronic myeloid leukemia (CML) by 24 weeks[5] - Enliven plans to report additional Phase 1 data for ELVN-001 and ELVN-002 in 2025, with an expected enrollment of approximately 60-100 patients across various lines of therapy[6] - The company continues to progress ELVN-002 in combination trials for HER2+ metastatic breast cancer (MBC) and colorectal cancer (CRC)[8] Market Opportunities - The company is encouraged by the recent accelerated approval of Scemblix for first-line CML, which may create a significant opportunity for ELVN-001 in second-line treatments[3]